Celularity Inc
Close on Oct 19, 2026
- Market cap
- $35.15M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 25, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 21, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 9, 2024 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 10, 2022 | During market hours | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 16, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 31, 2022 | During market hours | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 12, 2021 | During market hours | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 16, 2021 | During market hours | – | – | – |
Company guidance
Outlook given with results on Oct 25, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| combined Net Sales of our advanced biomaterial product and biobanking businesses | 2024 | $50.00M to $56.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Celularity filed with the SEC
Appoints Rick Gonzalez as Chief Commercial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces Closing of Transaction with NexGel
Material agreement · New financial obligation · Executive or director change · Other events · EX-99.1 to Form 8-K
Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Closing of Financing Transactions
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Full Year 2024 Operating and Financial Results
Results of operations · EX-99.1 to Form 8-K
Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
Other events · EX-99.1 to Form 8-K
Raises Full Year 2024 Guidance as
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
Material agreement · Other events · EX-99.1 to Form 8-K
Appoints Richard J. Berman to its Board of Directors
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. (“Celularity”) is a cellular and regenerative medicine company developing cryopreservable “off-the-shelf”
Regulation FD disclosure · EX-99.1 to Form 8-K
Celularity Announces Net Sales and Total Revenue Expectations
Results of operations · EX-99.1 to Form 8-K
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Carlos Ramirez, Senior Vice President
Other events · EX-99.1 to Form 8-K
Celularity Inc. Announces $3 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
THE NEXT EVOLUTION IN CELLULAR MEDICINE Investor Presentation June 2023
Other events · EX-99.1 to Form 8-K
Paul Graves, Chief Communications Officer
Other events · EX-99 to Form 8-K
Celularity Inc. Announces $6 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE
Other events · EX-99 to Form 8-K
Paul Graves SVP, Chief Communications Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
170 Park Ave, Florham Park, New Jersey 07932
Other events · EX-99.1 to Form 8-K
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celularity Inc. Announces $30 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Placental Derived Cell Type Program Indication Preclinical IND Submission Phase I Phase II ONCOLOGY Unmodified
Other events · EX-99.1 to Form 8-K
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy
Other events · EX-99.1 to Form 8-K
CYNK-001 ACUTE MYELOID LEUKEMIA UPDATE
Other events · EX-99.1 to Form 8-K
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K